Lijun International Pharmaceutical (Holding) Co. Ltd.


Lijun International Pharmaceutical Co., Limited is a Wanchai, Hong Kong–based investment holding company with two pharmaceutical business segments:

Business segments

The Group was listed on Hong Kong Stock Exchange in December 2005.
The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.

Subsidiaries

The Company’s subsidiaries include:
  • New Orient Limited in Hong Kong
  • Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province
  • Xi’an Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Shaanxi Province
  • Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.
The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.
Facing more merger and acquisition opportunities from medical reform in China, the Group is positioned for continuous mergers and acquisitions to promote its growth.